FOLH1 and prostate cancer: Regarding IONPs, when functionalized with prostate-specific membrane antigen (PSMA)-aptamers, they exhibited specific binding to target cancer cells compared to other nonspecific aptamers, as demonstrated by MRI in a heterotopic model of prostate cancer [180].